• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

患者对与血色素沉着症相关的铁过载进行静脉放血治疗的依从性。

Patient compliance with phlebotomy therapy for iron overload associated with hemochromatosis.

作者信息

Hicken Bret L, Tucker Diane C, Barton James C

机构信息

Department of Psychology, University of Alabama at Birmingham, Birmingham, Alabama, USA.

出版信息

Am J Gastroenterol. 2003 Sep;98(9):2072-7. doi: 10.1111/j.1572-0241.2003.07292.x.

DOI:10.1111/j.1572-0241.2003.07292.x
PMID:14499790
Abstract

OBJECTIVE

The aim of this study was to evaluate patient compliance with phlebotomy therapy of hemochromatosis-associated iron overload.

METHODS

We reviewed medical records of white adults with hemochromatosis and iron overload diagnosed during medical care. We defined three elements of compliance: 1) achieving iron depletion (serum ferritin </= 20 ng/ml); 2) timeliness of phlebotomies on a weekly or biweekly schedule to achieve iron depletion; and 3) participation in therapy to maintain serum ferritin </= 50 ng/ml. We evaluated associations of timeliness of phlebotomy and participation in maintenance therapy with these variables: age at diagnosis, sex, pretreatment serum ferritin concentration, HFE genotype, units of blood removed to achieve iron depletion, and presence or absence of cirrhosis at diagnosis.

RESULTS

A total of 118 patients were evaluable for iron depletion and 142 for maintenance therapy; 96.6% achieved iron depletion, and 33.1% and 43.2% followed weekly and biweekly schedules, respectively. Timeliness was not significantly associated with the variables we evaluated. In the first year of maintenance therapy, 84.0% of patients complied; the percentage of C282Y homozygotes complying was significantly greater than that of other patients. Average compliance with maintenance therapy decreased 6.8% annually; the mean follow-up after achieving iron depletion was 4.1 +/- 2.8 yr (range 0.6-9.7 yr).

CONCLUSIONS

Most patients with hemochromatosis diagnosed in medical care achieve iron depletion with phlebotomy; one-third tolerate and adhere to weekly phlebotomy. There is a constant rate of decline in the percentage of patients who comply with maintenance therapy.

摘要

目的

本研究旨在评估血色素沉着症相关铁过载患者对放血疗法的依从性。

方法

我们回顾了在医疗过程中被诊断为血色素沉着症和铁过载的白人成年人的病历。我们定义了依从性的三个要素:1)实现铁耗竭(血清铁蛋白≤20 ng/ml);2)按照每周或每两周一次的时间表进行放血以实现铁耗竭的及时性;3)参与治疗以维持血清铁蛋白≤50 ng/ml。我们评估了放血及时性和参与维持治疗与以下变量之间的关联:诊断时的年龄、性别、治疗前血清铁蛋白浓度、HFE基因型、实现铁耗竭所抽取的血液单位数以及诊断时是否存在肝硬化。

结果

共有118例患者可评估铁耗竭情况,142例可评估维持治疗情况;96.6%的患者实现了铁耗竭,分别有33.1%和43.2%的患者遵循每周和每两周一次的时间表。及时性与我们评估的变量无显著关联。在维持治疗的第一年,84.0%的患者依从;C282Y纯合子患者的依从百分比显著高于其他患者。维持治疗的平均依从性每年下降6.8%;实现铁耗竭后的平均随访时间为4.1±2.8年(范围0.6 - 9.7年)。

结论

在医疗过程中被诊断为血色素沉着症的大多数患者通过放血实现了铁耗竭;三分之一的患者耐受并坚持每周放血。依从维持治疗的患者百分比呈持续下降趋势。

相似文献

1
Patient compliance with phlebotomy therapy for iron overload associated with hemochromatosis.患者对与血色素沉着症相关的铁过载进行静脉放血治疗的依从性。
Am J Gastroenterol. 2003 Sep;98(9):2072-7. doi: 10.1111/j.1572-0241.2003.07292.x.
2
Efficacy and safety of phlebotomy to reduce transfusional iron overload in adult, long-term survivors of acute leukemia.放血疗法对成年急性白血病长期存活者减少输血性铁过载的疗效及安全性
Transfusion. 2004 Jun;44(6):833-7. doi: 10.1111/j.1537-2995.2004.03264.x.
3
Iron overload in patients receiving allogeneic hematopoietic stem cell transplantation: quantification of iron burden by a superconducting quantum interference device (SQUID) and therapeutic effectiveness of phlebotomy.异体造血干细胞移植患者的铁过载:超导量子干涉仪(SQUID)定量铁负荷和放血疗法的疗效。
Biol Blood Marrow Transplant. 2010 Jan;16(1):115-22. doi: 10.1016/j.bbmt.2009.09.011. Epub 2009 Sep 18.
4
Long term effects of phlebotomy on biochemical and histological parameters of chronic hepatitis C.
Am J Gastroenterol. 2002 Jan;97(1):133-7. doi: 10.1111/j.1572-0241.2002.05436.x.
5
The CD8+ T-lymphocyte profile as a modifier of iron overload in HFE hemochromatosis: an update of clinical and immunological data from 70 C282Y homozygous subjects.CD8+ T淋巴细胞谱作为HFE型血色病中铁过载的调节因素:70例C282Y纯合子受试者临床和免疫学数据的更新
Blood Cells Mol Dis. 2006 Jul-Aug;37(1):33-9. doi: 10.1016/j.bcmd.2006.04.004. Epub 2006 Jun 9.
6
Hepatic iron concentration in hereditary hemochromatosis does not saturate or accurately predict phlebotomy requirements.遗传性血色素沉着症中的肝脏铁浓度不会饱和,也不能准确预测放血治疗的需求量。
Am J Gastroenterol. 1998 Mar;93(3):346-50. doi: 10.1111/j.1572-0241.1998.00346.x.
7
Survival after liver transplantation in patients with hepatic iron overload: the national hemochromatosis transplant registry.肝铁过载患者肝移植后的生存率:国家血色素沉着症移植登记处
Gastroenterology. 2005 Aug;129(2):494-503. doi: 10.1016/j.gastro.2005.05.004.
8
Screening for hemochromatosis in asymptomatic subjects with or without a family history.对有或无家族病史的无症状受试者进行血色素沉着症筛查。
Arch Intern Med. 2006 Feb 13;166(3):294-301. doi: 10.1001/archinte.166.3.294.
9
Therapeutic erythrocytapheresis versus phlebotomy in the initial treatment of hereditary hemochromatosis - A pilot study.治疗性红细胞单采术与放血疗法用于遗传性血色素沉着症初始治疗的比较——一项试点研究
Transfus Apher Sci. 2007 Jun;36(3):261-7. doi: 10.1016/j.transci.2007.03.005. Epub 2007 Jun 13.
10
Effect of phlebotomy on lipid metabolism in subjects with hereditary hemochromatosis.放血疗法对遗传性血色素沉着症患者脂代谢的影响。
Metabolism. 2011 Jun;60(6):830-4. doi: 10.1016/j.metabol.2010.07.035. Epub 2010 Sep 16.

引用本文的文献

1
Diagnosis and Treatment of HFE-Linked Hemochromatosis.与HFE相关的血色素沉着症的诊断与治疗
Adv Exp Med Biol. 2025;1480:119-130. doi: 10.1007/978-3-031-92033-2_9.
2
The oral ferroportin inhibitor vamifeport prevents liver iron overload in a mouse model of hemochromatosis.口服铁转运蛋白抑制剂瓦米非泊汀可预防血色素沉着症小鼠模型中的肝脏铁过载。
Hemasphere. 2024 Sep 12;8(9):e147. doi: 10.1002/hem3.147. eCollection 2024 Sep.
3
Clinical practice guidelines on hemochromatosis: Asian Pacific Association for the Study of the Liver.血色病临床实践指南:亚太肝脏研究协会
Hepatol Int. 2023 Jun;17(3):522-541. doi: 10.1007/s12072-023-10510-3. Epub 2023 Apr 17.
4
Relationship between Iron deposition and T lymphocytes in children with β-thalassemia with haematopoietic stem cell transplantation.造血干细胞移植治疗β地中海贫血患儿铁沉积与T淋巴细胞的关系
Front Pediatr. 2022 Oct 17;10:939157. doi: 10.3389/fped.2022.939157. eCollection 2022.
5
Population Screening for Hereditary Haemochromatosis in Australia: Construction and Validation of a State-Transition Cost-Effectiveness Model.澳大利亚遗传性血色素沉着症的人群筛查:一种状态转换成本效益模型的构建与验证
Pharmacoecon Open. 2017 Mar;1(1):37-51. doi: 10.1007/s41669-016-0005-0.
6
Ruxolitinib for the treatment of patients with polycythemia vera.芦可替尼用于治疗真性红细胞增多症患者。
Expert Rev Hematol. 2015 Aug;8(4):391-401. doi: 10.1586/17474086.2015.1045869. Epub 2015 May 17.
7
Erythrocytapheresis compared with whole blood phlebotomy for the treatment of hereditary haemochromatosis.红细胞单采术与全血采血术治疗遗传性血色素沉着症的比较。
Blood Transfus. 2014 Jan;12 Suppl 1(Suppl 1):s84-9. doi: 10.2450/2013.0128-13. Epub 2013 Oct 23.
8
Patient compliance based on genetic medicine: a literature review.基于基因医学的患者依从性:文献综述
J Community Genet. 2014 Jan;5(1):31-48. doi: 10.1007/s12687-013-0160-2. Epub 2013 Aug 10.
9
Aceruloplasminemia: a rare disease - diagnosis and treatment of two cases.无铜蓝蛋白血症:一种罕见疾病——两例病例的诊断与治疗
Rev Bras Hematol Hemoter. 2011;33(5):389-92. doi: 10.5581/1516-8484.20110104.
10
A phase 1/2, dose-escalation trial of deferasirox for the treatment of iron overload in HFE-related hereditary hemochromatosis.一项评估地拉罗司治疗 HFE 相关性遗传性血色素沉着症铁过载的 1/2 期、剂量递增临床试验。
Hepatology. 2010 Nov;52(5):1671-779. doi: 10.1002/hep.23879.